October 26, 2018 - 9:00am

Health and Human Services Commission, John H. Winters Human Services Complex, Public Hearing Room
701 West 51st St.
Austin Texas, 78751


Webcasting Available

  1. Call to order
  2. Approval of minutes from July 27, 2018 (vote required)
  3. New member introductions and terms
  4. Ethics policy refresher
  5. Vice-chair election (vote required)
  6. New business

    Public comment on drug classes and therapeutic and clinical drug reviews to be reviewed for the Medicaid Preferred Drug List (PDL):

    1. Androgenic agents
    2. Antibiotics, GI
    3. Antibiotics, topical
    4. Antibiotics, vaginal
    5. Antiemetics/Antivertigo agents
    6. Antifungals, oral
    7. Antifungals, topical
    8. Antihistamines, first generation
    9. Antiparasitics, topical
    10. Antipsychotics
    11. Antivirals, oral
    12. Antivirals, topical
    13. Bone resorption suppression and related agents
    14. Colony stimulating factors
    15. Cytokine and CAM antagonists
    16. Epinephrine, self-injected
    17. GI motility, chronic
    18. Growth hormone
    19. Hepatitis C agents
    20. Hypoglycemics, incretin mimetics/enhancers
    21. Hypoglycemics, insulin and related agents
    22. Hypoglycemics, meglitinides
    23. Hypoglycemics, metformins
    24. Hypoglycemics, SGLT2
    25. Hypoglycemics, TZD
    26. Immunomodulators, atopic dermatitis
      aa. Macrolides/Ketolides
      bb. Ophthalmics, glaucoma agents
      cc. Opiate dependence treatments
      dd. Pediatric vitamin preparations
      ee. Penicillins
      ff. Tetracyclines

    Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL:

    1. Aimovig / Antimigraine agents, other
    2. Mircera / Erythropoiesis stimulating proteins
    3. Osmolex ER / Antiparkinson’s agents
    4. Retacrit / Erythropoiesis stimulating proteins
    5. Roxybond / Analgesics, Narcotics short

  7. Executive work session

    Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.

  8. Announcements of drugs recommended for the Medicaid PDL (vote required)
  9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC
    1. Report on recent retrospective DUR interventions:
      1. Benzodiazepine anxiolytics and controlled sedative hypnotics
      2. Diabetes disease management
      3. Rheumatoid arthritis management
    2. Report on recent retrospective DUR intervention outcomes:
      1. Opioids during pregnancy
      2. Polypharmacy
      3. Stroke prevention
    3. Retrospective DUR proposals (vote required)
      1. Management of psychotropic drug in adults
      2. Medication adherence
  10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required)
    1. Calcitonin gene-related peptide receptor (CGRP) Antagonist - new criteria
    2. Cytokine and CAM antagonists - addition of Olumiant criteria
  11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required)
    1. 5-HT3 receptor antagonists
    2. Attention deficit disorder medications
    3. GLP-1 receptor agonists
    4. Oral antidiabetic agents
    5. Pramlintide
    6. Substance P / Neurokinin 1 receptor antagonists
  12. Adjourn
  13. Next meeting date: January 25, 2019

Contact: Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O. Castoreno, DUR/PDL Oversight Specialist, Health and Human Services Commission, Medicaid and CHIP Services Department, at 512-707-6112 or Maribel.Castoreno@hhsc.state.tx.us.

Information regarding submission of written comments and application to provide public testimony before the committee can be found at: https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-meetings.

This meeting is open to the public. No reservations are required, and there is no cost to attend this meeting.

People with disabilities who wish to attend the meeting and require auxiliary aids or services should contact Castoreno at 512-707-6112 at least 72 hours before the meeting so appropriate arrangements can be made.